metformin

P1, N=60, Recruiting, Beijing QL Biopharmaceutical Co.,Ltd | Not yet recruiting --> Recruiting

Management included custom orthopedic footwear with supramalleolar orthotic (SMO) inserts, endurance-focused physical therapy, gabapentin for neuropathic pain, metformin for dysglycemia, atorvastatin for lipid and atherosclerotic cardiovascular disease (ASCVD) risk reduction, antihypertensive therapy for blood-pressure control, and longitudinal cardiac surveillance with electrocardiogram (ECG), echocardiography, and ambulatory rhythm monitoring. This case highlights the multisystem nature of LMNA-related disease and the importance of recognizing overlapping adipose, neurologic, metabolic, and cardiac manifestations as part of a unified disease process requiring coordinated neuromuscular, endocrine, and cardiology follow-up.

P=N/A, N=28, Recruiting, University of Castilla-La Mancha

Breast cancer cells (i.e., MCF7 and MDA-MB231) infected with a combination of recombinant HSV-1 viruses that express granulocyte-macrophage colony-stimulating factor (GM-CSF) and metformin exhibit a synergistic effect in promoting the expression of interferon-ϒ (IFN-ϒ) found within peripheral blood mononuclear cells (PBMCs) and exerting apoptotic and cytotoxic effects in the mentioned malignant cells. The online version contains supplementary material available at 10.1007/s12088-025-01523-7.

Further evidence from hydrogen bond analysis revealed that the ligand contributed to complex stability by maintaining sporadic yet regular polar interactions throughout the trajectory. These findings suggest that CID 222300 is a promising lead compound capable of interacting with the mTOR target in a stable and targeted manner, indicating its potential as a novel therapeutic agent against HNC.

In vivo, metformin reduces tumor cell infiltration in the spleen and modulates NF-κB and STAT5 signaling, although its effect on overall disease progression is limited. These results identify metformin as a multifaceted agent targeting both metabolic and survival pathways in BPDCN, supporting its potential as a therapeutic strategy in this rare malignancy.

P2, N=110, Recruiting, Dana-Farber Cancer Institute | N=180 --> 110

Such combined treatment showed promising synergistic interaction via several molecular pathways, which is well tolerated and readily applicable strategy to improve the therapeutic outcome of PDT in cancer cell treatment.

P4, N=14, Completed, University of Virginia | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026

P4, N=22, Terminated, University of Illinois at Chicago | N=300 --> 22 | Recruiting --> Terminated; Low recruitment rate and an inability to meet power.

P=N/A, N=200, Active, not recruiting, Riphah International University

P3, N=120, Completed, Central South University | Trial completion date: Jun 2027 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026 | Recruiting --> Completed